BET1

Across TCGA pan-cancer cohorts, BET1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated BET1 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher BET1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated BET1 expression acts as an unfavorable survival marker, although some lineages such as COAD and LUAD show a favorable association.

CCRCC, COAD, and PDAC are the cancer types where BET1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	II,III,IV	0.340	0.776	<.001	65	view →
COAD	DFS	Median	III,IV	1.000	0.832	.030	12	view →
PDAC	OS	Median	All	0.788	0.902	.006	10	view →
LUAD	OS	Quartile	III,IV	0.867	0.321	.007	5	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

BET1–CCRCC (DFS)

Open the CCRCC breakdown →